---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-342695"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2026-08-10T21:19:34+00:00"
generated_at: "2026-08-10T21:22:08.842055+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences launches $400M at-the-market equity offering via Guggenheim

## Summary
- Filed prospectus supplement on Aug 10, 2026 to sell up to $400M of common stock under ATM sales agreement with Guggenheim Securities.
- Offering uses automatic shelf registration on Form S-3ASR filed Nov 7, 2025; shares sold at market prices.
- Gibson, Dunn & Crutcher issued legal opinion on the shares, filed as exhibit to this 8-K.

## SEC filing metadata
- accession: 0001193125-26-342695
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2026-08-10T21:19:34+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312526342695/0001193125-26-342695-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312526342695/d132277d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-342695
- JSON: https://secwatch.observer/filing/0001193125-26-342695.json
- Plain text: https://secwatch.observer/filing/0001193125-26-342695.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.